四环医药公告,集团旗下轩竹生物自主研发的ALK抑制剂1类创新药地罗阿克片(曾用名“达希替尼”,商品名:轩菲宁 )获得中国国家药品监督管理局(NMPA)批准上市,用于治疗间变性淋巴瘤激酶(ALK)阳性的晚期非小细胞肺癌(NSCLC)。地罗阿克具有四大核心优势,包括起效迅速、抑瘤强度卓越、缓解持久、生存获益显著。根据灼识咨询数据,2024年,中国ALK阳性NSCLC患者91200人,预计2032年将达...
Source Link四环医药公告,集团旗下轩竹生物自主研发的ALK抑制剂1类创新药地罗阿克片(曾用名“达希替尼”,商品名:轩菲宁 )获得中国国家药品监督管理局(NMPA)批准上市,用于治疗间变性淋巴瘤激酶(ALK)阳性的晚期非小细胞肺癌(NSCLC)。地罗阿克具有四大核心优势,包括起效迅速、抑瘤强度卓越、缓解持久、生存获益显著。根据灼识咨询数据,2024年,中国ALK阳性NSCLC患者91200人,预计2032年将达...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.